Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-trial access roll-over study of ribociclib + letrozole
jRCT2031220246Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoint: Treatment-emergent adverse events. Started Jul 2022; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031220246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220246.